Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter licenses gentamicin surgical implant

Baxter licenses gentamicin surgical implant

26th August 2008

Baxter has signed a licensing agreement for the gentamicin surgical implant from Innocoll Pharmaceuticals.

The company said this antibiotic surgical product may reduce post-operative cost and complications by lowering the incidence of surgical site infections.

Under the terms of the deal, Baxter will pay an initial license fee in addition to contingent clinical, regulatory and commercial milestone payments.

It will also contribute to registration fees and phase III clinical development costs.

The gentamicin surgical implant is the first biodegradable, leave-behind antibiotic surgical sponge to be used as an adjunct therapy for the prevention and treatment of surgical site infections.

Baxter said this licensing agreement, which covers the US, will add to its biosurgical portfolio and offer doctors a new method for reducing the risk of post-operative complications during surgery.

Ron Lloyd, vice-president and general manager of the biosurgery business at Baxter, said: “We look forward to making this product available for surgeons to help alleviate the burden of infections occurring from surgery.”

He added the product complements the company’s existing product portfolio for tissue sealing haemostasis.

Last month, Baxter International raised its yearly financial outlook following the publication of its second-quarter financial results.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.